Akebia Therapeutics (AKBA) Cash from Financing Activities (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Cash from Financing Activities data on file, last reported at -$926000.0 in Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 101.24% year-over-year to -$926000.0 in Q1 2026; TTM through Mar 2026 was -$2.9 million, a 102.77% decrease from a year earlier, with the FY2025 full-year figure at $72.9 million, up 46.84% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$926000.0, up from -$4.8 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for AKBA reached as high as $74.9 million in Q1 2025 and fell as low as -$32.9 million in Q3 2022.
• Historically, Cash from Financing Activities has averaged $6.5 million across 5 years, with a median of $50000.0 in 2023.
• Across the five-year window, Cash from Financing Activities sank 128900.0% in 2023 and jumped 2346.0% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at -$1000.0 in 2022, then sank by 128900.0% to -$1.3 million in 2023, then surged by 1830.62% to $22.3 million in 2024, then sank by 121.72% to -$4.8 million in 2025, then soared by 80.9% to -$926000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$926000.0 in Q1 2026, -$4.8 million in Q4 2025, and $1.1 million in Q3 2025.